Oral version of Ozempic leads to 15% weight loss; landfill battle is 'a textbook case of environmental racism'

An oral version of semaglutide, the drug marketed as Ozempic, led to dramatic weight loss in a trial enrolling people with obesity.

May 22, 2023 Check out STAT+

Sponsored By

LISELOTTE SABROE/AFP/Getty Images STAT+ | Novo says oral version of Ozempic leads to 15% weight loss Semaglutide is already a blockbuster in injectable form as Wegovy and Ozempic. The data on a pill form could bolster demand even more. By Damian Garde Making sense of AI research in medicine, in one slide Research on artificial intelligence in health care runs the gamut of rewarding to relatively useless. Here's how one expert breaks AI down. By Brittany Trang STAT+ | In early trial, drug appears to reduce harmful protein buildup in heart An Astra Zeneca-licensed compound reversed some effects of ATTR-CM, a condition in which amyloid protein builds up in the heart. By Elaine Chen 'A textbook case of environmental racism': The battle over the Brookhaven Landfill The area of North Bellport on Long Island sits in the shadows of a massive landfill and has the lowest life expectancy on Long Island. By Nicholas St. Fleur Opinion: Checklists to screen for patients' social needs aren't helping Hospitals like to brag about systems intended to identify patients who need help. But the approach isn't working. By Sanjay Basu

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser